SPRB - Why Is Rare Endocrine Disorder-Focused Spruce Biosciences Stock Plummeting On Thursday? | Benzinga
Wednesday, Spruce Biosciences Inc (NASDAQ:SPRB) released topline results from its CAHmelia-203 Phase 2b study of tildacerfont in adult classic congenital adrenal hyperplasia (CAH) and its CAHptain-205 study of tildacerfont in pediatric classic CAH.
CAH refers to a group of genetic disorders that involve the adrenal glands, a pair of small organs located above the kidneys.
The CAHmelia-203 study did not achieve the primary efficacy endpoint of the assessment of dose response for the change in A4 from baseline to week 12.
- 200mg QD of tildacerfont demonstrated a placebo-adjusted reduction from baseline in A4 of -2.6% at week 12 with a non-significant p-value.
- Compliance with study medication and GC was low, with approximately 50% ...